Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound

Experimental Neurology

Volumn 248, Issue , 2013, Pages 16-29

  Jordão, Jessica F ^a,b   Thévenot, Emmanuel ^a   Markham Coultes, Kelly ^a   Scarcelli, Tiffany ^a,b   Weng, Ying Qi ^a   Xhima, Kristiana ^a   O'Reilly, Meaghan ^a   Huang, Yuexi ^a   McLaurin, JoAnne ^b   Hynynen, Kullervo ^a,b   Aubert, Isabelle ^a,b  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimer's disease; Amyloid beta peptide; Astrocytes; Autoantibodies; Focused ultrasound; Immunoglobulin; Microglia; Transgenic mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN REGION; CELL ACTIVATION; CONTROLLED STUDY; GLIA CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MALE; MICROGLIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; TRANSCRANIAL FOCUSED ULTRASOUND; TRANSGENIC MOUSE; ULTRASOUND THERAPY; WESTERN BLOTTING;

ALZHEIMER'S DISEASE; AMYLOID-BETA PEPTIDE; ASTROCYTES; AUTOANTIBODIES; FOCUSED ULTRASOUND; IMMUNOGLOBULIN; MICROGLIA; TRANSGENIC MICE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; FEMALE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MICE; MICE, TRANSGENIC; NEUROGLIA; PLAQUE, AMYLOID; ULTRASONOGRAPHY;

EID: 84879380571     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.05.008     Document Type: Article

References (62)

1. Adams R.A., et al. The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 2007, 204:571-582.
2. Bacskai B.J., et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 2001, 7:369-372.
3. Banks W.A., Terrell B., Farr S.A., Robinson S.M., Nonaka N., Morley J.E. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002, 23:2223-2226.
4. Bard F., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
5. Burgess A., Aubert I., Hynynen K. Focused ultrasound: crossing barriers to treat Alzheimer's disease. Ther. Deliv. 2011, 2:281-286.
6. Burgess A., Ayala-Grosso C.A., Ganguly M., Jordão J.F., Aubert I., Hynynen K. Targeted delivery of neural stem cells to the brain using MRI-guided focused ultrasound to disrupt the blood-brain barrier. PLoS One 2011, 6:e27877.
7. Burgess A., Huang Y., Querbes W., Sah D.W., Hynynen K. Focused ultrasound for targeted delivery of siRNA and efficient knockdown of Htt expression. J. Control. Release 2012, 163:125-129.
8. Chen K.S., et al. Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice. Prog. Brain Res 1998, 117:327-334.
9. Chishti M.A., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J. Biol. Chem. 2001, 276:21562-21570.
10. Cho E.E., Drazic J., Ganguly M., Stefanovic B., Hynynen K. Two-photon fluorescence microscopy study of cerebrovascular dynamics in ultrasound-induced blood-brain barrier opening. J. Cereb. Blood Flow Metab. 2011, 31:1852-1862.
11. Choi J.J., Selert K., Gao Z., Samiotaki G., Baseri B., Konofagou E.E. Noninvasive and localized blood-brain barrier disruption using focused ultrasound can be achieved at short pulse lengths and low pulse repetition frequencies. J. Cereb. Blood Flow Metab. 2011, 31:725-737.
12. Chopra R., Curiel L., Staruch R., Morrison L., Hynynen K. An MRI-compatible system for focused ultrasound experiments in small animal models. Med. Phys. 2009, 36:1867-1874.
13. Deane R., et al. IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. J. Neurosci. 2005, 25:11495-11503.
14. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
15. Deng J., et al. The role of caveolin-1 in blood-brain barrier disruption induced by focused ultrasound combined with microbubbles. J. Mol. Neurosci. 2012, 46:677-687.
16. Dodel R., et al. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 2002, 52:253-256.
17. Du Y., et al. Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain 2003, 126:1935-1939.
18. Familian A., Eikelenboom P., Veerhuis R. Minocycline does not affect amyloid beta phagocytosis by human microglial cells. Neurosci. Lett. 2007, 416:87-91.
19. Frautschy S.A., Yang F., Irrizarry M., Hyman B., Saido T.C., Hsiao K., Cole G.M. Microglial response to amyloid plaques in APPsw transgenic mice. Am. J. Pathol. 1998, 152:307-317.
20. Hawkes C.A., Deng L., Fenili D., Nitz M., McLaurin J. In vivo uptake of beta-amyloid by non-plaque associated microglia. Curr. Alzheimer Res. 2012, 9:890-901.
21. Huang Q., Deng J., Wang F., Chen S., Liu Y., Wang Z., Cheng Y. Targeted gene delivery to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Exp. Neurol. 2012, 233:350-356.
22. Hyman B.T., Smith C., Buldyrev I., Whelan C., Brown H., Tang M.X., Mayeux R. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann. Neurol. 2001, 49:808-810.
23. Hynynen K., McDannold N., Vykhodtseva N., Jolesz F.A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001, 220:640-646.
24. Hynynen K., McDannold N., Martin H., Jolesz F.A., Vykhodtseva N. The threshold for brain damage in rabbits induced by bursts of ultrasound in the presence of an ultrasound contrast agent (Optison). Ultrasound Med. Biol. 2003, 29:473-481.
25. Hynynen K., McDannold N., Sheikov N.A., Jolesz F.A., Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. NeuroImage 2005, 24:12-20.
26. Ito D., Imai Y., Ohsawa K., Nakajima K., Fukuuchi Y., Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 1998, 57:1-9.
27. Ito D., Tanaka K., Suzuki S., Dembo T., Fukuuchi Y. Enhanced expression of Iba1, ionized calcium-binding adapter molecule 1, after transient focal cerebral ischemia in rat brain. Stroke 2001, 32:1208-1215.
28. Jordao J.F., et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS One 2010, 5:e10549.
29. Jordão J.F., et al. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS One 2010, 5:e10549.
30. Joshi S., Ergin A., Wang M., Reif R., Zhang J., Bruce J.N., Bigio I.J. Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy. J. Neurooncol. 2010, 104:11-19.
31. Kinoshita M., McDannold N., Jolesz F.A., Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11719-11723.
32. Kinoshita M., McDannold N., Jolesz F.A., Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem. Biophys. Res. Commun. 2006, 340:1085-1090.
33. Koenigsknecht-Talboo J., et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J. Neurosci. 2008, 28:14156-14164.
34. Kotilinek L.A., et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22:6331-6335.
35. Kraft A.W., et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J 2013, 27:187-198.
36. Magga J., et al. Human intravenous immunoglobulin provides protection against Abeta toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J. Neuroinflammation 2010, 7:90.
37. Masliah E., Sisk A., Mallory M., Mucke L., Schenk D., Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F beta-amyloid precursor protein and Alzheimer's disease. J. Neurosci. 1996, 16:5795-5811.
38. McDannold N., Vykhodtseva N., Raymond S., Jolesz F.A., Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med. Biol. 2005, 31:1527-1537.
39. McDannold N., Vykhodtseva N., Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys. Med. Biol. 2006, 51:793-807.
40. McDannold N., Clement G.T., Black P., Jolesz F., Hynynen K. Transcranial magnetic resonance imaging- guided focused ultrasound surgery of brain tumors: initial findings in 3 patients. Neurosurgery 2010, 66:323-332. (discussion 332).
41. McDannold N., Arvanitis C.D., Vykhodtseva N., Livingstone M.S. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012, 72:3652-3663.
42. McLaurin J., et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat. Med. 2002, 8:1263-1269.
43. Miller G. Drug targeting. Breaking down barriers. Science 2002, 297:1116-1118.
44. Nicoll J.A., et al. Abeta species removal after abeta42 immunization. J. Neuropathol. Exp. Neurol. 2006, 65:1040-1048.
45. O'Reilly M.A., Hynynen K. Ultrasound enhanced drug delivery to the brain and central nervous system. Int. J. Hyperthermia 2012, 28:386-396.
46. O'Reilly M.A., Waspe A.C., Ganguly M., Hynynen K. Focused-ultrasound disruption of the blood-brain barrier using closely-timed short pulses: influence of sonication parameters and injection rate. Ultrasound Med. Biol. 2011, 37:587-594.
47. Patel M.M., Goyal B.R., Bhadada S.V., Bhatt J.S., Amin A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009, 23:35-58.
48. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
49. Ransohoff R.M., Perry V.H. Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 2009, 27:119-145.
50. Raymond S.B., Treat L.H., Dewey J.D., McDannold N.J., Hynynen K., Bacskai B.J. Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS One 2008, 3:e2175.
51. Salahuddin T.S., Johansson B.B., Kalimo H., Olsson Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study. Acta Neuropathol. 1988, 77:5-13.
52. Schenk D., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
53. Sheikov N., McDannold N., Vykhodtseva N., Jolesz F., Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med. Biol. 2004, 30:979-989.
54. Sheikov N., McDannold N., Sharma S., Hynynen K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med. Biol. 2008, 34:1093-1104.
55. Sigurdsson E.M., et al. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J. Neurosci. 2004, 24:6277-6282.
56. Solomon B., Koppel R., Frankel D., Hanan-Aharon E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:4109-4112.
57. Takata K., et al. Microglial amyloid-beta1-40 phagocytosis dysfunction is caused by high-mobility group box protein-1: implications for the pathological progression of Alzheimer's disease. Int. J. Alzheimers Dis. 2012, 2012:685739.
58. Thévenot E., et al. Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound. Hum. Gene Ther. 2012, 23:1144-1155.
59. Treat L.H., McDannold N., Vykhodtseva N., Zhang Y., Tam K., Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int. J. Cancer 2007, 121:901-907.
60. Wilcock D.M., et al. Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J. Neurosci. 2003, 23:3745-3751.
61. Wilcock D.M., et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci. 2004, 24:6144-6151.
62. Yeh C.Y., Vadhwana B., Verkhratsky A., Rodriguez J.J. Early astrocytic atrophy in the entorhinal cortex of a triple transgenic animal model of Alzheimer's disease. ASN Neuro 2011, 3:271-279.